Alkermes plc (ALKS) Bundle
An Overview of Alkermes plc (ALKS)
General Summary of Alkermes plc (ALKS)
Alkermes plc is a global biopharmaceutical company headquartered in Dublin, Ireland, with operations in the United States. The company focuses on developing innovative medicines for central nervous system (CNS) disorders, addiction, and oncology.
| Company Details | Information |
|---|---|
| Headquarters | Dublin, Ireland |
| Founded | 2011 |
| Stock Exchange Listing | NASDAQ: ALKS |
Key Products and Services
- ARISTADA (aripiprazole lauroxil) - Long-acting injectable antipsychotic medication
- VIVITROL - Treatment for alcohol and opioid dependence
- LYBALVI - Oral antipsychotic medication for schizophrenia and bipolar disorder
Financial Performance in Latest Reporting Period
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $1.15 billion |
| Product Sales Revenue | $555.7 million |
| Net Income | $89.4 million |
Industry Leadership
Alkermes plc stands as a prominent player in the biopharmaceutical industry, particularly in CNS disorder treatments. The company's innovative pipeline and strategic focus on complex therapeutic areas differentiate it from competitors.
| Research & Development | 2023 Investment |
|---|---|
| R&D Expenses | $377.6 million |
| Active Clinical Trials | 8 ongoing programs |
Market Position
- Top 5 company in CNS pharmaceutical market
- Recognized for innovative drug delivery technologies
- Strong presence in addiction treatment market
Mission Statement of Alkermes plc (ALKS)
Mission Statement of Alkermes plc (ALKS)
Alkermes plc (NASDAQ: ALKS) mission statement focuses on developing innovative pharmaceutical solutions to address complex central nervous system (CNS) disorders and serious chronic diseases.
Core Mission Components
Pharmaceutical Innovation
Alkermes committed to developing advanced pharmaceutical technologies with specific focus areas:
- CNS disorder treatments
- Addiction management medications
- Schizophrenia interventions
| Research Investment | 2024 Allocation |
|---|---|
| R&D Expenditure | $326.7 million |
| CNS Research Budget | $187.4 million |
Treatment Portfolio
Current pharmaceutical portfolio targeting specific medical conditions:
- VIVITROL® for alcohol and opioid dependence
- ARISTADA® for schizophrenia management
- LYBALVI® for schizophrenia and bipolar disorder
| Product | 2023 Revenue |
|---|---|
| VIVITROL® | $341.2 million |
| ARISTADA® | $289.7 million |
Research Pipeline
Ongoing clinical development initiatives targeting unmet medical needs:
- Advanced neurological disorder treatments
- Long-acting injectable medications
- Proprietary drug delivery technologies
| Pipeline Stage | Number of Programs |
|---|---|
| Preclinical Stage | 6 programs |
| Clinical Trial Stage | 4 programs |
Vision Statement of Alkermes plc (ALKS)
Vision Statement of Alkermes plc (ALKS) in 2024
Strategic Positioning in Neuroscience and PharmaceuticalsAlkermes plc focuses on developing innovative medicines in neuroscience and oncology with a specific emphasis on addressing complex central nervous system disorders.
Key Vision Components
Therapeutic Focus Areas| Disease Category | Primary Research Target |
|---|---|
| Neurological Disorders | Schizophrenia, Addiction, Depression |
| Oncology | Advanced Cancer Treatments |
- Advanced drug delivery technologies
- Long-acting injectable medications
- Proprietary microsphere platform
Innovation Metrics
| R&D Investment | 2024 Value |
|---|---|
| Annual Research Expenditure | $308.7 million |
| Patent Portfolio | 87 active patents |
Nasdaq-listed pharmaceutical company headquartered in Dublin, Ireland, with significant operational presence in Massachusetts, USA.
Pipeline Development Strategy
- Continuous investment in novel therapeutic solutions
- Focus on unmet medical needs
- Precision medicine approach
| Metric | 2024 Value |
|---|---|
| Total Revenue | $1.12 billion |
| Market Capitalization | $3.8 billion |
Core Values of Alkermes plc (ALKS)
Core Values of Alkermes plc (ALKS) in 2024
Innovation and Scientific Excellence
Alkermes demonstrates commitment to innovation through significant R&D investments.
| R&D Expenditure 2023 | Total Research Investments |
|---|---|
| $285.4 million | 19.4% of total revenue |
- 3 new drug candidates in clinical development
- 12 active research programs across neurological and addiction treatment areas
- 38 patent applications filed in 2023
Patient-Centered Approach
Alkermes focuses on developing treatments for complex medical conditions.
| Patient Treatment Areas | Number of Patients Served |
|---|---|
| Schizophrenia | Approximately 125,000 patients annually |
| Addiction Treatment | Over 90,000 patients treated |
Ethical Business Practices
Commitment to transparency and corporate responsibility.
| Compliance Metrics | 2023 Data |
|---|---|
| Ethical Compliance Training | 100% employee participation |
| Corporate Governance Ratings | A- from MSCI ESG |
Sustainability Commitment
Environmental and social responsibility initiatives.
- Carbon emissions reduction: 22% since 2019
- Renewable energy usage: 35% of total energy consumption
- Waste reduction: 18% decrease in manufacturing waste
Collaborative Research Approach
Strategic partnerships and collaborative research efforts.
| Research Collaborations | 2023 Details |
|---|---|
| Academic Partnerships | 7 active research collaborations |
| Pharmaceutical Partnerships | 4 active joint development programs |
Alkermes plc (ALKS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.